{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T07:04:02Z","timestamp":1765609442257},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2010,4,1]],"date-time":"2010-04-01T00:00:00Z","timestamp":1270080000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Med Klin"],"published-print":{"date-parts":[[2010,4]]},"DOI":"10.1007\/s00063-010-1046-2","type":"journal-article","created":{"date-parts":[[2010,5,8]],"date-time":"2010-05-08T04:58:28Z","timestamp":1273294708000},"page":"314-318","source":"Crossref","is-referenced-by-count":4,"title":["Schwerer Verlauf einer Miliartuberkulose bei einem 34-j\u00e4hrigen Patienten mit Colitis ulcerosa und HIV-Infektion unter einer TNF-\u03b1-Antik\u00f6rper-Therapie"],"prefix":"10.1007","volume":"105","author":[{"given":"Jonas","family":"Zeitz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Milo","family":"Huber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerhard","family":"Rogler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,5,9]]},"reference":[{"key":"1046_CR1","first-page":"443","volume":"2","author":"J.A. Streeton","year":"1998","unstructured":"Streeton JA, Desem N, Jones SL. Sensitivity and specificity of a gamma interferon blood test for tuberculosis infection. Int J Tuberc Lung Dis 1998;2:443\u201350.","journal-title":"Int J Tuberc Lung Dis"},{"key":"1046_CR2","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","volume":"359","author":"S.B. Hanauer","year":"2002","unstructured":"Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002;359:1541\u20139.","journal-title":"Lancet"},{"key":"1046_CR3","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1056\/NEJM199710093371502","volume":"337","author":"S.R. Targan","year":"1997","unstructured":"Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997;337:1029\u201335.","journal-title":"N Engl J Med"},{"key":"1046_CR4","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1056\/NEJMoa067594","volume":"357","author":"W.J. Sandborn","year":"2007","unstructured":"Sandborn WJ, Feagan BG, Stoinov S, et al. Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med 2007;357:228\u201338.","journal-title":"N Engl J Med"},{"key":"1046_CR5","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1056\/NEJMoa062897","volume":"357","author":"S. Schreiber","year":"2007","unstructured":"Schreiber S, Khaliq-Kareemi M, Lawrance IC, et al. Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med 2007;357:239\u201350.","journal-title":"N Engl J Med"},{"key":"1046_CR6","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1056\/NEJMoa030815","volume":"350","author":"B.E. Sands","year":"2004","unstructured":"Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 2004;350:876\u201385.","journal-title":"N Engl J Med"},{"key":"1046_CR7","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1053\/j.gastro.2005.03.003","volume":"128","author":"G. Jarnerot","year":"2005","unstructured":"Jarnerot G, Hertervig E, Friis-Liby I, et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology 2005;128:1805\u201311.","journal-title":"Gastroenterology"},{"key":"1046_CR8","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1056\/NEJMoa050516","volume":"353","author":"P. Rutgeerts","year":"2005","unstructured":"Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005;353:2462\u201376.","journal-title":"N Engl J Med"},{"key":"1046_CR9","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1097\/QCO.0b013e32832dda55","volume":"22","author":"R.S. Wallis","year":"2009","unstructured":"Wallis RS. Infectious complications of tumor necrosis factor blockade. Curr Opin Infect Dis 2009;22:403\u20139.","journal-title":"Curr Opin Infect Dis"},{"key":"1046_CR10","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa011110","volume":"345","author":"J. Keane","year":"2001","unstructured":"Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001;345:1098\u2013104.","journal-title":"N Engl J Med"},{"key":"1046_CR11","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1002\/art.24632","volume":"60","author":"F. Tubach","year":"2009","unstructured":"Tubach F, Salmon D, Ravaud P, et al. Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: the three-year prospective French Research Axed on Tolerance of Biotherapies registry. Arthritis Rheum 2009;60:1884\u201394.","journal-title":"Arthritis Rheum"},{"key":"1046_CR12","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/j.1365-2036.2009.04112.x","volume":"31","author":"M.J. Shale","year":"2010","unstructured":"Shale MJ, Seow CH, Coffin CS, et al. Review article: Chronic viral infection in the anti-tumour necrosis factor therapy era in inflammatory bowel disease. Aliment Pharmacol Ther 2010;31:20\u201334.","journal-title":"Aliment Pharmacol Ther"},{"issue":"Suppl3","key":"1046_CR13","doi-asserted-by":"crossref","first-page":"S199","DOI":"10.1086\/429998","volume":"41","author":"S. Ehlers","year":"2005","unstructured":"Ehlers S. Tumor necrosis factor and its blockade in granulomatous infections: differential modes of action of infliximab and etanercept? Clin Infect Dis 2005;41:Suppl 3:S199\u2013203.","journal-title":"Clin Infect Dis"},{"key":"1046_CR14","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.autrev.2008.07.011","volume":"8","author":"A. Lalvani","year":"2008","unstructured":"Lalvani A, Millington KA. Screening for tuberculosis infection prior to initiation of anti-TNF therapy. Autoimmun Rev 2008;8:147\u201352.","journal-title":"Autoimmun Rev"},{"key":"1046_CR15","doi-asserted-by":"crossref","first-page":"177","DOI":"10.7326\/0003-4819-149-3-200808050-00241","volume":"149","author":"M. Pai","year":"2008","unstructured":"Pai M, Zwerling A, Menzies D. Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: an update. Ann Intern Med 2008;149:177\u201384.","journal-title":"Ann Intern Med"},{"key":"1046_CR16","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1007\/s10096-008-0519-1","volume":"27","author":"M. Bocchino","year":"2008","unstructured":"Bocchino M, Matarese A, Bellofiore B, et al. Performance of two commercial blood IFN-gamma release assays for the detection of Mycobacterium tuberculosis infection in patient candidates for anti-TNF-alpha treatment. Eur J Clin Microbiol Infect Dis 2008;27:907\u201313.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"1046_CR17","volume-title":"Manuel de la tuberculose","author":"Ligue Pulmonaire Suisse.","year":"2007","unstructured":"Ligue Pulmonaire Suisse. Manuel de la tuberculose, 2\u00e8me \u00e9dn. Berne: Ligue Pulmonaire Suisse, 2007 ( http:\/\/www.tbinfo.ch ).","edition":"2\u00e8me \u00e9dn."},{"key":"1046_CR18","first-page":"620","volume":"137","author":"C. Beglinger","year":"2007","unstructured":"Beglinger C, Dudler J, Mottet C, et al. Screening for tuberculosis infection before the initiation of an anti-TNF-alpha therapy. Swiss Med Wkly 2007;137:620\u20132.","journal-title":"Swiss Med Wkly"},{"key":"1046_CR19","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1136\/gut.2007.132407","volume":"57","author":"L.A. Bourikas","year":"2008","unstructured":"Bourikas LA, Kourbeti IS, Koutsopoulos AV, et al. Disseminated tuberculosis in a Crohn's disease patient on anti-TNF alpha therapy despite chemoprophylaxis. Gut 2008;57:425.","journal-title":"Gut"},{"key":"1046_CR20","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.autrev.2008.07.009","volume":"8","author":"M. Galeazzi","year":"2008","unstructured":"Galeazzi M, Giannitti C, Manganelli S, et al. Treatment of rheumatic diseases in patients with HCV and HIV infection. Autoimmun Rev 2008;8:100\u20133.","journal-title":"Autoimmun Rev"},{"key":"1046_CR21","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1136\/ard.2007.081513","volume":"67","author":"E.J. Cepeda","year":"2008","unstructured":"Cepeda EJ, Williams FM, Ishimori ML, et al. The use of anti-tumour necrosis factor therapy in HIV-positive individuals with rheumatic disease. Ann Rheum Dis 2008;67:710\u20132.","journal-title":"Ann Rheum Dis"},{"key":"1046_CR22","first-page":"1353","volume":"34","author":"G. Linardaki","year":"2007","unstructured":"Linardaki G, Katsarou O, Ioannidou P, et al. Effective etanercept treatment for psoriatic arthritis complicating concomitant human immunodeficiency virus and hepatitis C virus infection. J Rheumatol 2007;34:1353\u20135.","journal-title":"J Rheumatol"}],"container-title":["Medizinische Klinik"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00063-010-1046-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00063-010-1046-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00063-010-1046-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T02:13:25Z","timestamp":1558577605000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00063-010-1046-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,4]]},"references-count":22,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2010,4]]}},"alternative-id":["1046"],"URL":"https:\/\/doi.org\/10.1007\/s00063-010-1046-2","relation":{},"ISSN":["0723-5003","1615-6722"],"issn-type":[{"value":"0723-5003","type":"print"},{"value":"1615-6722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,4]]}}}